<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415961</url>
  </required_header>
  <id_info>
    <org_study_id>CI-CMS-005</org_study_id>
    <nct_id>NCT00415961</nct_id>
  </id_info>
  <brief_title>Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety</brief_title>
  <official_title>Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conor Medsystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Getz Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Conor Medsystems</source>
  <brief_summary>
    <textblock>
      This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to
      the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in
      in-segment late lumen loss at 9 months after treatment of a single de novo lesion per vessel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a complementary, multi-center, open-label, single-arm trial investigating
      angiographic and clinical patient outcomes in Japan. Historical data from the 2-arm
      randomized COSTAR II trial will be used for comparison.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late lumen loss at 9 months, as measured by QCA.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device, lesion and procedure success; MACE at 30 days and 8 months, Angiographic restenosis at 9 months; Clinically driven Target Lesion Revascularization at 8 months</measure>
    <time_frame>MACE at 30 days and 8 months, Angiographic restenosis at 9 months; Clinically driven Target Lesion Revascularization at 8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoStar Paclitaxel drug eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoStar Paclitaxel Drug-Eluting Coronary Stent System</intervention_name>
    <description>CoStar Paclitaxel Drug-Eluting Coronary Stent System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria

          -  Eligible for percutaneous coronary intervention (PCI)

          -  Documented stable or unstable angina pectoris (Class I, II, III or IV), documented
             ischemia, or documented silent ischemia

          -  Documented LVEF ≥25% within the last 6 weeks.

          -  Eligible for coronary artery bypass graft surgery (CABG)

        Exclusion Criteria:

        General Exclusion Criteria: -

          -  Known sensitivity to paclitaxel or polymeric matrices.

          -  Planned treatment with any other PCI device in the target vessel(s).

          -  MI within 72 hours prior to the index procedure

          -  Patient is in cardiogenic shock

          -  Cerebrovascular Accident (CVA) within the past 6 months

          -  Acute or chronic renal dysfunction (creatinine &gt;2.0 mg/dl or &gt;150 µmol/L)

          -  Contraindication to ASA or to ticlopidine

          -  Thrombocytopenia

          -  Active GI bleeding within past three months

          -  Known allergy to cobalt chromium

          -  Any prior true anaphylactic reaction to contrast agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ShonanKamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura City</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2006</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shigeru Saito, MD</name_title>
    <organization>ShonanKamakura General Hospital</organization>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>Drug-eluting stent (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

